Dr. Christopher J. Anker
Claim this profileUniversity of Vermont Medical Center
Studies Lung Cancer
Studies Small Cell Lung Cancer
5 reported clinical trials
16 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage III
Stage I
2Small Cell Lung Cancer
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Christopher J. Anker is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
More about Christopher J. Anker
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Christopher J. Anker has experience with
- Cisplatin
- Carboplatin
- Etoposide
- Durvalumab
- Ipilimumab
- Nivolumab
Breakdown of trials Christopher J. Anker has run
Lung Cancer
Small Cell Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher J. Anker specialize in?
Christopher J. Anker focuses on Lung Cancer and Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage III.
Is Christopher J. Anker currently recruiting for clinical trials?
Yes, Christopher J. Anker is currently recruiting for 2 clinical trials in Burlington Vermont. If you're interested in participating, you should apply.
Are there any treatments that Christopher J. Anker has studied deeply?
Yes, Christopher J. Anker has studied treatments such as Cisplatin, Carboplatin, Etoposide.
What is the best way to schedule an appointment with Christopher J. Anker?
Apply for one of the trials that Christopher J. Anker is conducting.
What is the office address of Christopher J. Anker?
The office of Christopher J. Anker is located at: University of Vermont Medical Center, Burlington, Vermont 05401 United States. This is the address for their practice at the University of Vermont Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.